AstraZeneca PLC (LON:AZN – Get Free Report) insider Michel Demare purchased 2,000 shares of AstraZeneca stock in a transaction dated Friday, September 13th. The stock was bought at an average cost of GBX 118 ($1.56) per share, with a total value of £2,360 ($3,117.57).
AstraZeneca Price Performance
Shares of LON:AZN opened at £120.16 ($158.73) on Tuesday. AstraZeneca PLC has a 52 week low of GBX 9,461 ($124.98) and a 52 week high of £133.88 ($176.86). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market cap of £186.25 billion, a P/E ratio of 3,851.28, a PEG ratio of 0.93 and a beta of 0.17. The company has a 50-day moving average price of £125.81 and a 200 day moving average price of £119.05.
AstraZeneca Cuts Dividend
The company also recently announced a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a GBX 77.60 ($1.03) dividend. The ex-dividend date of this dividend was Thursday, August 8th. This represents a yield of 0.64%. AstraZeneca’s payout ratio is currently 7,500.00%.
Analysts Set New Price Targets
View Our Latest Stock Analysis on AstraZeneca
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- The 3 Best Fintech Stocks to Buy Now
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Consumer Staples Stocks, Explained
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- The Risks of Owning Bonds
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.